Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International, Multicentre, Open- Label, Interventional Phase IV Clinical Study to Investigate the Efficacy and Safety of Tildrakizumab 100 mg in Patients With Moderate- Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE)

NCT04229836 is registered in ClinicalTrials.gov with Almirall, S.A. as lead sponsor.

NCT NCT04229836
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04229836 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International, Multicentre, Open- Label, Interventional Phase IV Clinical Study to Investigate the Efficacy and Safety of Tildrakizumab 100 mg in Patients With Moderate- Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE)
Lead sponsor
Almirall, S.A.
Phase
Phase 4
Overall status
Completed
Start date
December 17, 2019
Completion date
November 15, 2021
Enrollment
178 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis